JTE 451

Drug Profile

JTE 451

Alternative Names: JTE-451

Latest Information Update: 20 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Japan Tobacco
  • Class Antiallergics
  • Mechanism of Action Immunomodulators; Nuclear receptor subfamily 1 group F member 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autoimmune disorders; Hypersensitivity; Plaque psoriasis

Most Recent Events

  • 20 Jun 2017 Akros Pharma completes a phase I trial in Plaque psoriasis in Canada (PO) (NCT03018509)
  • 01 Aug 2016 Phase-I clinical trials in Autoimmune disorders (PO)
  • 01 Aug 2016 Phase-I clinical trials in Hypersensitivity (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top